Выступлние на конференции Genetics of Aging and Longevity

[quantumpete]

De-novo anti-ageing drug design

1. crisis of modern age-related diseases treatment
2. “targeted” medicines targeting rare phenotypes, not the root causes
3. example of recent targeted cancer drugs “problem”
4. “end-of-life costs”-problem, see “how doctors die”
5. antiageing drug design workflow[b]
6. antagonistic paleotrophy - reason for pharmacological intervention
7. aging genes identification
8. member of one or more diseases network
9. evolutionary conservation
10. implication in silencing/knockout experiments leading to lifespan extension
11. QUANTUM KNOW-HOW: design of pharmacological agent
12. difference between chemical and silencing “knockout”; case study - 1 (PFK) - it well may be i have no time for that, can list in b.i as example of modulating both ways
13. pre- and clinical trials; what to do if there is no indication as ageing?
14. case study - 2 (shortcut to market example: viral diseases)[c]
15. idea (age-1 knockout, diseases, worm and Moskalev data, conservativity of the pathway)
16. pi3K-nfkb signalling and viral diseases, aspirine!
17. in-vitro proof of concept
18. preclinical trials: in-vivo studies, longer indications, toxicology studies, longer studies, older animals, mice lifespan control experiment
19. future drugs are anti-ageing drugs!
20. joke: good heuristics to keep the drug developers life longer, if not healthier :)